相关实验视频
Updated: Jul 9, 2025

11:45
Quantifying Agonist Activity at G Protein-coupled Receptors
Published on: December 26, 2011
19.3K
通过线性反应理论,有效地区分弱性蛋白-连接体相互作用的激素和竞争对手
Anthony J Davolio1, Wojciech J Jankowski1, Csilla Várnai2,3
1Theory of Condensed Matter Group, Department of Physics, University of Cambridge, Cambridge CB3 0HE, U.K.
ACS omega
|December 4, 2023
概括
了解受体行为:本研究使用先进的模拟对胺5-HT3A受体进行了激动剂和竞争性对抗剂之间的区别. 这种方法有效地预测了连接体相互作用,降低了计算成本.
科学领域:
- 生物化学 生物化学
- 计算生物学 计算生物学
- 药理学 药理学是指药理学的学科.
背景情况:
- 血清素3A型 (5-HT3A) 受体在神经传递中起着至关重要的作用.
- 区分激动剂和竞争性对抗剂对于药物开发至关重要.
- 目前分析连接体相互作用的方法可能是计算密集的.
研究的目的:
- 阐明在5-HT3A受体上将激动剂与竞争对手的激动剂区分开来的分子机制.
- 开发一种计算高效的方法来预测连接体行为.
主要方法:
- 在5-HT3A受体上使用并行化蒙特卡洛模拟.
- 线性响应理论被用来预测形状变化.
- 使用共变量张量和波近似来建模结合点动态.
主要成果:
- 该研究成功地区分了多重连接体的激动因子和竞争性对抗因子.
- 开发的方法需要计算上昂贵的计算,每种蛋白质只需要一次.
- 预测的形状变化与联结体诱导的效应相关.
结论:
- 这种方法提供了一种可行的和有效的策略,用于在5-HT3A受体上区分配体类型.
- 这些发现对合理设计针对这种受体的药物有影响.
- 该方法的效率可以加速药物发现过程.
相关概念视频
The Two-State Receptor Model
1.9K
The two-state receptor model explains a drug's interaction with receptors, such as G protein-coupled receptors and ligand-gated ion channels, to induce or inhibit a biological response. When no natural ligands are present, a receptor exists in an equilibrium of inactive (Ri) and active (Ra) conformations. The inactive form does not produce a response, while the active form generates a basal effect known as constitutive activity.
The binding affinity of a drug determines its interaction with...
The binding affinity of a drug determines its interaction with...
1.9K
Cooperative Allosteric Transitions
7.9K
Cooperative allosteric transitions can occur in multimeric proteins, where each subunit of the protein has its own ligand-binding site. When a ligand binds to any of these subunits, it triggers a conformational change that affects the binding sites in the other subunits; this can change the affinity of the other sites for their respective ligands. The ability of the protein to change the shape of its binding site is attributed to the presence of a mix of flexible and stable segments in the...
7.9K
Drug-Receptor Interactions
5.2K
Drug-receptor interaction describes the binding of receptors by drugs, but not all drug-receptor interactions result in activation and tissue response. For instance, the binding of agonists activates the receptor to generate a cellular reaction, while antagonists bind to receptors without causing their activation.
Several parameters, such as the drug's affinity for its receptor and its efficacy, which is its ability to activate the receptor, determine the drug's effect on the tissue....
Several parameters, such as the drug's affinity for its receptor and its efficacy, which is its ability to activate the receptor, determine the drug's effect on the tissue....
5.2K
Drug-Receptor Interaction: Antagonist
3.0K
An antagonist is a drug that binds strongly to a receptor without activating it. An antagonist prevents other molecules, such as neurotransmitters or hormones, from binding to the receptor and triggering a cellular response. Such interaction effectively hinders the normal physiological processes mediated by the receptor, resulting in various pharmacological effects depending on the specific receptor targeted.
Antagonists can be classified as competitive or noncompetitive based on their...
Antagonists can be classified as competitive or noncompetitive based on their...
3.0K
Drug-Receptor Interaction: Agonist
2.5K
Agonists are drugs that interact with specific receptors in the body to produce a biological response. When an agonist binds to a receptor, it activates or enhances the receptor's function, leading to physiological effects. The interaction between agonist drugs and receptors is crucial for their therapeutic action in various medical treatments.
Agonists can bind to receptors in different ways. Some agonists bind directly to the receptor's active site, mimicking the endogenous...
Agonists can bind to receptors in different ways. Some agonists bind directly to the receptor's active site, mimicking the endogenous...
2.5K
Allosteric Regulation
58.0K
Allosteric regulation of enzymes occurs when the binding of an effector molecule to a site that is different from the active site causes a change in the enzymatic activity. This alternate site is called an allosteric site, and an enzyme can contain more than one of these sites. Allosteric regulation can either be positive or negative, resulting in an increase or decrease in enzyme activity. Most enzymes that display allosteric regulation are metabolic enzymes involved in the degradation or...
58.0K

